Juvenile Psoriatic Arthritis
Dermatology·MeSH: Arthritis, Juvenile
Prevalence
133.0 / 100K
Incidence
6.0 / 100K/yr
5 drugs in development·4 companies·4 clinical trials
Drug Pipeline by Phase
Phase 3(4)
Phase 4(1)
| Drug | Company |
|---|---|
| Deucravacitinib | BRISTOL MYERS SQUIBB CO (BMY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Juvenile Psoriatic Arthritis?
BioSniper tracks 5 drugs in development for Juvenile Psoriatic Arthritis across 4 companies.
How many clinical trials target Juvenile Psoriatic Arthritis?
There are 4 clinical trials targeting Juvenile Psoriatic Arthritis tracked by BioSniper.
What is the prevalence of Juvenile Psoriatic Arthritis?
The estimated prevalence of Juvenile Psoriatic Arthritis is approximately 133.0 per 100,000 population.
Deep-dive into Juvenile Psoriatic Arthritis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis